Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

被引：0
|
作者：
Gulati, Shuchi [1 ]
Elsisi, Zizi [2 ]
Deoghare, Smruti [2 ]
Eckman, Mark [2 ]
机构：
[1] Univ Cincinnati, Vontz Ctr Mol Studies, Cincinnati, OH USA
[2] Univ Cincinnati, Cincinnati, OH USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124756
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
328
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis
    Young Eun Shin
    Arun Kumar
    Monica Hwang
    Martha Mackey
    Wenchen (Kenneth) Wu
    Clinical Drug Investigation, 2022, 42 : 1075 - 1083
  • [22] Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin
    Fiorelli, Elisa Maria
    Rossi, Roberta Elisa
    INTERNAL AND EMERGENCY MEDICINE, 2018, 13 (07) : 1089 - 1091
  • [23] Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin
    Elisa Maria Fiorelli
    Roberta Elisa Rossi
    Internal and Emergency Medicine, 2018, 13 : 1089 - 1091
  • [24] Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism in Spain.
    Munoz Martin, Andres J.
    Diaz, Enrique Gallardo
    Crespo, Carlos
    Domenech, Roma Masana
    Soto, Javier
    Arumi, Daniel
    Fernandez, Susana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer A Randomized Clinical Trial
    Schrag, Deborah
    Uno, Hajime
    Rosovsky, Rachel
    Rutherford, Cynthia
    Sanfilippo, Kristen
    Villano, John L.
    Drescher, Monic
    Jayaram, Nagesh
    Holmes, Chris
    Feldman, Lawrence
    Zattra, Ottavia
    Farrar-Muir, Haley
    Cronin, Christine
    Basch, Ethan
    Weiss, Anna
    Connors, Jean M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (22): : 1924 - 1933
  • [26] Inclusion of a heparin neutralizer in the plasma diluent confers specificity to the FXa direct oral anticoagulants rivaroxaban, apixaban, and edoxaban in an anti-Xa chromogenic assay
    Goldford, M.
    Calhoon, W.
    Nguyen, D.
    Woodhams, B.
    Morris, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 15 - 15
  • [27] Direct oral anticoagulant vs low molecular weight heparin for the treatment of venous thromboembolism associated with malignancy: a meta- analysis
    Lastimosa, H.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [28] Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails
    Wongsaengsak, Sariya
    Ball, Somedeb
    Khandelwal, Nuvneet
    Tikue, Alay
    Motes, Arunee
    Jahan, Nusrat
    Thein, Kyaw Zin
    Tijani, Lukman
    BLOOD, 2019, 134
  • [29] Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats
    O'Connell, Casey
    Escalante, Carmen P.
    Goldhaber, Samuel Z.
    McBane, Robert
    Connors, Jean M.
    Raskob, Gary E.
    ONCOLOGIST, 2021, 26 (01): : E8 - E16
  • [30] TREATMENT OF CANCER ASSOCIATED VENOUS THROMBOEMBOLISM WITH APIXABAN COMPARED TO LOW MOLECULAR WEIGHT HEPARIN: A META-ANALYSIS
    Rahman, Hammad
    Khan, Muhammad Shahzeb
    Hammad, Tehseen
    Sharma, Saurabh
    Kaluski, Edo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2069 - 2069
12345